Thus, together with therapeutic applications of GLP-1 and related analogs, inhibitors for the dipeptidyl peptidase-4 (DPP-4), the enzyme that cleaves GLP-1 and GLP-2, and GLP-1R agonists that have a prolonged half-life due to reduced degradation by DPP-4 are currently being used for the treatment of T2D and obesity [57]. Here, GLP1R is linked to type 2 diabetes mellitus.